Business services providers thrive by solving complex operational challenges for their clients, allowing them to focus on ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

Equifax Inc. Annual stock financials by MarketWatch. View the latest EFX financial statements, income statements and financial ratios.

EFX is now being further evaluated in three ongoing Phase 3 trials targeting all stages of MASH. EFX, Akero's lead candidate, is an FGF21 analog designed for once-weekly dosing.